These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16569872)

  • 1. Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease.
    Prabu-Jeyabalan M; King NM; Nalivaika EA; Heilek-Snyder G; Cammack N; Schiffer CA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1518-21. PubMed ID: 16569872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.
    Nalam MN; Ali A; Altman MD; Reddy GS; Chellappan S; Kairys V; Ozen A; Cao H; Gilson MK; Tidor B; Rana TM; Schiffer CA
    J Virol; 2010 May; 84(10):5368-78. PubMed ID: 20237088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
    Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
    Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Jul; 437(2):199-204. PubMed ID: 23792096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis.
    Chellappan S; Kiran Kumar Reddy GS; Ali A; Nalam MN; Anjum SG; Cao H; Kairys V; Fernandes MX; Altman MD; Tidor B; Rana TM; Schiffer CA; Gilson MK
    Chem Biol Drug Des; 2007 May; 69(5):298-313. PubMed ID: 17539822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the mechanism of drug resistance: X-ray structure analysis of multi-drug resistant HIV-1 protease ritonavir complex.
    Liu Z; Yedidi RS; Wang Y; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Feb; 431(2):232-8. PubMed ID: 23313846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 protease.
    Nalam MN; Peeters A; Jonckers TH; Dierynck I; Schiffer CA
    J Virol; 2007 Sep; 81(17):9512-8. PubMed ID: 17596316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
    Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
    J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conserved hydrogen bonds and water molecules in MDR HIV-1 protease substrate complexes.
    Liu Z; Wang Y; Yedidi RS; Dewdney TG; Reiter SJ; Brunzelle JS; Kovari IA; Kovari LC
    Biochem Biophys Res Commun; 2013 Jan; 430(3):1022-7. PubMed ID: 23261453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation.
    Bandyopadhyay P; Meher BR
    Chem Biol Drug Des; 2006 Feb; 67(2):155-61. PubMed ID: 16492163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
    Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.
    Prashar V; Bihani SC; Das A; Rao DR; Hosur MV
    Biochem Biophys Res Commun; 2010 Jun; 396(4):1018-23. PubMed ID: 20471372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
    Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
    J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 protease folding and the design of drugs which do not create resistance.
    Broglia R; Levy Y; Tiana G
    Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An orally bioavailable pyrrolinone inhibitor of HIV-1 protease: computational analysis and X-ray crystal structure of the enzyme complex.
    Smith AB; Hirschmann R; Pasternak A; Yao W; Sprengeler PA; Holloway MK; Kuo LC; Chen Z; Darke PL; Schleif WA
    J Med Chem; 1997 Aug; 40(16):2440-4. PubMed ID: 9258349
    [No Abstract]   [Full Text] [Related]  

  • 20. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V; Bihani SC; Ferrer JL; Hosur MV
    Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.